Vidmantas Petraitis Selected Research

Invasive Pulmonary Aspergillosis

1/2021	Pharmacodynamics of Posaconazole in Experimental Invasive Pulmonary Aspergillosis: Utility of Serum Galactomannan as a Dynamic Endpoint of Antifungal Efficacy.
9/2020	Modeling Invasive Aspergillosis: How Close Are Predicted Antifungal Targets?
1/2020	Combination Therapy with Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1→3)-β-d-Glucan Synthesis, and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis.
1/2017	Endpoint Assessment in Rabbit Models of Invasive Pulmonary Aspergillosis and Mucormycosis.
1/2017	Combination Therapy with Isavuconazole and Micafungin for Treatment of Experimental Invasive Pulmonary Aspergillosis.
1/2016	Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints.
1/2016	Pharmacokinetics and Concentration-Dependent Efficacy of Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis.
8/2015	Effects of host response and antifungal therapy on serum and BAL levels of galactomannan and (1→3)-β-D-glucan in experimental invasive pulmonary aspergillosis.
5/2015	Pharmacodynamics of amphotericin B deoxycholate, amphotericin B lipid complex, and liposomal amphotericin B against Aspergillus fumigatus.
6/2014	Host biomarkers of invasive pulmonary aspergillosis to monitor therapeutic response.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Vidmantas Petraitis Research Topics

Disease

21	Invasive Pulmonary Aspergillosis 01/2021 - 01/2002
13	Body Weight (Weight, Body) 10/2021 - 01/2002
13	Infections 10/2021 - 07/2003
10	Aspergillosis 09/2020 - 01/2002
8	Lung Injury 09/2020 - 01/2002
7	Candidiasis (Moniliasis) 11/2017 - 06/2002
7	Pulmonary Aspergillosis 09/2013 - 01/2002
6	Meningoencephalitis 02/2021 - 01/2008
5	Pulmonary Infarction 01/2016 - 01/2002
4	Mycoses (Diseases, Fungus) 04/2022 - 12/2003
4	Infarction (Infarctions) 09/2020 - 06/2009
3	Hematologic Neoplasms (Hematological Malignancy) 04/2022 - 04/2017
3	Phaeohyphomycosis 02/2021 - 12/2015
3	Mucormycosis 12/2018 - 01/2013
3	Invasive Candidiasis 11/2017 - 01/2006
2	Bacteremia 10/2021 - 01/2020
2	Neutropenia 03/2020 - 08/2015
2	Pneumonia (Pneumonitis) 01/2020 - 01/2019
2	Wounds and Injuries (Trauma) 10/2017 - 12/2015
1	Vulvovaginal Candidiasis 04/2022
1	Chronic Disease (Chronic Diseases) 10/2021
1	Endophthalmitis (Ophthalmia) 01/2021
1	Candidemia 01/2021
1	Osteomyelitis 11/2019
1	Diabetes Mellitus 10/2017
1	Arthritis (Polyarthritis) 04/2017
1	Invasive Fungal Infections 01/2017
1	Hyalohyphomycosis 12/2015
1	Fungal Meningitis 02/2015
1	Fungal Lung Diseases 11/2014
1	Chronic Granulomatous Disease 01/2011
1	Inflammation (Inflammations) 01/2011
1	Burkholderia Infections 01/2011
1	Bacterial Infections (Bacterial Infection) 01/2011

Drug/Important Bio-Agent (IBA)

15	Amphotericin B (Amphotericin)FDA LinkGeneric 09/2020 - 01/2002
11	galactomannanIBA 01/2021 - 01/2002
10	Biomarkers (Surrogate Marker)IBA 09/2020 - 04/2006
9	isavuconazoleIBA 02/2021 - 11/2014
8	TriazolesIBA 02/2021 - 06/2003
8	Micafungin (FK463)FDA Link 02/2021 - 06/2002
8	EchinocandinsIBA 11/2017 - 01/2002
7	liposomal amphotericin B FDA Link 02/2021 - 06/2002
5	Antifungal AgentsIBA 04/2022 - 02/2015
4	EnzymesIBA 04/2022 - 10/2004
4	Deoxycholic Acid (Sodium Deoxycholate)IBA 09/2020 - 01/2002
3	ibrexafungerpIBA 04/2022 - 01/2020
3	posaconazole FDA Link 01/2021 - 03/2020
3	Caspofungin (Cancidas)FDA Link 09/2020 - 01/2002
3	Voriconazole (Vfend)FDA LinkGeneric 09/2020 - 06/2009
3	Anidulafungin FDA Link 09/2020 - 06/2009
3	Methylprednisolone FDA LinkGeneric 03/2020 - 02/2015
3	deoxycholate drug combination amphotericin BIBA 05/2015 - 10/2006
3	ER 30346 (ravuconazole)IBA 10/2006 - 06/2003
2	TriterpenesIBA 04/2022 - 01/2020
2	Tazobactam Drug Combination Piperacillin (Zosyn)FDA LinkGeneric 10/2021 - 10/2004
2	ProdrugsIBA 01/2021 - 01/2016
2	Pharmaceutical PreparationsIBA 09/2020 - 01/2002
2	PolyenesIBA 11/2017 - 12/2003
2	Adrenal Cortex Hormones (Corticosteroids)IBA 10/2017 - 04/2017
2	polyglucosanIBA 11/2010 - 11/2008
2	Dihydrotachysterol (AT 10)IBA 06/2009 - 05/2005
2	2- amino- 4- methylenecyclopentane- 1- carboxylic acidIBA 05/2005 - 10/2004
2	Fluconazole (Zonal)FDA LinkGeneric 05/2005 - 10/2004
2	Isoleucine-tRNA LigaseIBA 05/2005 - 10/2004
2	AntigensIBA 10/2004 - 01/2002
1	glucan synthaseIBA 04/2022
1	Anti-Infective Agents (Microbicides)IBA 10/2021
1	Vancomycin FDA LinkGeneric 10/2021
1	Meropenem (Merrem)FDA LinkGeneric 10/2021
1	Cytarabine (Cytosar-U)FDA LinkGeneric 03/2020
1	ceftazidime drug combination avibactamIBA 01/2020
1	carbapenemaseIBA 01/2020
1	MannansIBA 11/2019
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 11/2019
1	tazobactam drug combination ceftolozaneIBA 01/2019
1	PorinsIBA 01/2019
1	eravacyclineIBA 01/2018
1	VaccinesIBA 01/2017
1	LipopeptidesIBA 12/2015
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 08/2015
1	Nucleic AcidsIBA 11/2014
1	Annexin A1IBA 06/2014
1	C-Reactive ProteinIBA 06/2014
1	Proteins (Proteins, Gene)FDA Link 06/2014
1	HaptoglobinsIBA 06/2014
1	Glucose (Dextrose)FDA LinkGeneric 09/2013
1	trypticase-soy broth (trypticase soy)IBA 09/2013
1	AgarIBA 09/2013
1	NADPH Oxidases (NAD(P)H oxidase)IBA 01/2011
1	Oxidants (Oxidizing Agents)IBA 01/2011
1	Serine Proteases (Serine Protease)IBA 01/2011

Therapy/Procedure

24	Therapeutics 04/2022 - 01/2002
2	Vascular Access Devices (Arterial Line) 10/2021 - 12/2015
2	Transplantation 10/2017 - 04/2017
1	Hematopoietic Stem Cell Transplantation 04/2022
1	Intravenous Infusions 01/2020
1	Operative Surgical Procedures 10/2017
1	Debridement 10/2017
1	Central Venous Catheters 12/2015
1	Punctures 12/2015